Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long‐term tenofovir: Virological and clinical implications
Anders Boyd, Joël Gozlan, Sarah Maylin, Constance Delaugerre, Gilles Peytavin, Pierre‐Marie Girard, Fabien Zoulim, Karine Lacombe – 19 April 2014 – Tenofovir (TDF) is considered the ideal treatment for patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV). However, certain coinfected patients exhibit incomplete viral suppression, with persistent, and sometimes transient, bouts of HBV replication. The reasons for this, including clinical effect, are unclear.